Retrospective Study of Bleeding Risk with Concomitant Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor and Anticoagulation

Retrospective Study ◽

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Bleeding Risk ◽

Vascular Endothelial ◽

Everolimus zur Behandlung des metastasierten Nierenzellkarzinoms nach Versagen der ersten VEGFr-TKI(Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor)-Therapie: Ergebnisse einer Interimsanalyse einer nichtinterventionellen Studie

Karger Kompass Onkologie ◽

10.1159/000356898 ◽

2014 ◽

Vol 1 (1) ◽

pp. 28-29

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Inhibition of Chronic and Acute Skin Inflammation by Treatment with a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

American Journal Of Pathology ◽

10.2353/ajpath.2008.071074 ◽

2008 ◽

Vol 173 (1) ◽

pp. 265-277 ◽

Cited By ~ 59

Author(s):

Cornelia Halin ◽

Hermann Fahrngruber ◽

Josef G. Meingassner ◽

Guido Bold ◽

Amanda Littlewood-Evans ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Skin Inflammation ◽

Vascular Endothelial ◽

Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization

Ophthalmic Research ◽

10.1159/000324994 ◽

2012 ◽

Vol 47 (1) ◽

pp. 13-18 ◽

Cited By ~ 12

Author(s):

Uğurcan Keskin ◽

Yüksel Totan ◽

Remzi Karadağ ◽

Mesut Erdurmuş ◽

Bahri Aydın

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Corneal Neovascularization ◽

Vascular Endothelial ◽

Inhibitory Effects ◽

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-2436 ◽

2010 ◽

Vol 16 (7) ◽

pp. 2187-2197 ◽

Cited By ~ 10

Author(s):

Marlies H.G. Langenberg ◽

Petronella O. Witteveen ◽

Jeanine M. Roodhart ◽

Henk M.W. Verheul ◽

Marja Mergui-Roelvink ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis

Translational Research ◽

10.1016/j.trsl.2007.01.003 ◽

2007 ◽

Vol 149 (3) ◽

pp. 103-106 ◽

Cited By ~ 14

Author(s):

Mani Keshtgarpour ◽

Arkadiusz Z. Dudek

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3045 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3045-3045

Author(s):

M. H. Langenberg ◽

P. Witteveen ◽

J. M. Roodhart ◽

M. P. Lolkema ◽

H. Verheul ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR [KDR]-TKI), in a model of ZD1839 (‘Iressa’) resistance

European Journal of Cancer ◽

10.1016/s0959-8049(02)80842-5 ◽

2002 ◽

Vol 38 ◽

pp. S60-S61

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity

The Journal of Dermatology ◽

10.1111/j.1346-8138.2007.00304.x ◽

2007 ◽

Vol 34 (7) ◽

pp. 419-429 ◽

Cited By ~ 4

Author(s):

Aisaku YAMAMOTO ◽

Hideaki WATANABE ◽

Hirohiko SUEKI ◽

Takako NAKANISHI ◽

Hajime YASUHARA ◽

...

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Contact Hypersensitivity ◽

Vascular Endothelial ◽

Faculty Opinions recommendation of Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.4854958.4781057 ◽

2010 ◽

Author(s):

Alba Brandes ◽

Enrico Franceschi

Keyword(s):

Growth Factor ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Recurrent Glioblastoma ◽

Vascular Endothelial ◽

595 Effect of Ketoconazole On Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor

European Journal of Cancer ◽

10.1016/s0959-8049(12)72392-4 ◽

2012 ◽

Vol 48 ◽

pp. 182-183 ◽

Cited By ~ 1

Author(s):

M. Cotreau ◽

N. Siebers ◽

L. Massmanian ◽

A. Strahs ◽

D. Vargo

Keyword(s):

Growth Factor ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽